Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth

Shanghai, China, April 17, 2026 – Asieris Pharmaceuticals today released its 2025 Annual Report. Highlights include strong progress under its Commercialization 2.0 strategy, continued commercial momentum, the China approval of CEVIRA®, the world’s first non-invasive treatment for precancerous cervical lesions, and multiple key pipeline advances. With these milestones in place, 2026 is expected to mark […] The post Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth appeared first on Asieris Pharmaceuticals .